Smooth Muscle Cell Migration Promoting Activity of Plasma Predicts Restenosis in Patients with Peripheral Arterial Occlusive Disease Undergoing Angioplasty

Summary

Background

Efficacy of percutaneous transluminal angioplasty (PTA) is limited by restenosis occurring in a large proportion of patients. Smooth muscle cell (SMC) migration is a major pathomechanism of restenosis. We studied SMC migration inducing activity of plasma from patients with peripheral arterial occlusive disease (PAOD) undergoing PTA.

Methods and Results

SMC migration was determined in a two-dimensional assay system after addition of 1/25 plasma dilutions. Mean increase in migration area was 65.5 ± 33.8% in normal controls and 67.7 ± 53.2% in patients with PAOD. 6 hours after PTA, plasmatic migration inducing activity was largely unchanged. In 19/30 patients with restenosis (6 months after PTA) migration promoting activity (82.7 ± 60.0) was significantly higher than in 11/30 patients with patent vessels (41.8 ± 21.0; p = 0.03). No correlation of clinical risk factors with outcome was observed. A weak correlation was found between plasmatic migration promoting activity and levels of epidermal growth factor and transforming growth factor-β.

Conclusion

The capacity of human plasma to stimulate SMC migration in tissue culture can be used to assess the risk for restenosis after PTA in patients with PAOD.

Key words

Peripheral arterial occlusive disease - angioplasty - restenosis - smooth muscle cells - growth factors

• References

• 1 Johnston KW. Femoral and popliteal arteries: Reanalysis of results of balloon angioplasty. Radiology 1992; 183: 767-71.
• 2 Davies MG, Hagen PO. Pathobiology of intimal hyperplasia. Br J Surg 1994; 81: 1254-69.
• 3 van Hinsbergh VW. Regulatory functions of the coronary endothelium. Mol Cell Biochem 1992; 116: 163-9.
• 4 Kishi Y, Numano F. In vitro study of vascular endothelial injury by activated platelets and its prevention. Atherosclerosis 1989; 76: 95-101.
• 5 Harker LA. Role of platelets and thrombosis in mechanisms of acute occlusion and restenosis after angioplasty. Am J Cardiol 1987; 60: 20B-28B.
• 6 Jawien A, Bowen DFPope, Lindner V, Schwartz SM, Clowes AW. Platelet-derived growth factor promotes smooth muscle migration and intimal thickening in a rat model of balloon angioplasty. J Clin Invest 1992; 89: 507-11.
• 7 Mitsumata M, Gamou S, Shimizu N, Yoshida Y. Response of atherosclerotic intimal smooth muscle cells to epidermal growth factor in vitro. Arterioscler Thromb 1994; 14: 1364-71.
• 8 Jackson CL, Reidy MA. Basic fibroblast growth factor: its role in the control of smooth muscle cell migration. Am J Pathol 1993; 143: 1024-31.
• 9 Li Z, Alavi MZ, Moore S. The proliferation of neointimal smooth muscle cells cultured from rabbit aortic explants 15 weeks after de-endothelialization by a balloon catheter. Int J Exp Pathol 1994; 75: 169-77.
• 10 Motani A, Rutherford C, Anggard EE, Ferns GA. Insulin-like growth factor binding protein-1 inhibits arterial smooth muscle cell proliferation in vitro but does not reduce the neointimal response to balloon catheter injury. Atherosclerosis 1995; 118: 57-66.
• 11 Madri JA, Bell L, Merwin JR. Modulation of vascular cell behaviour by transforming growth factor beta. Mol Reprod Dev 1992; 32: 121-6.
• 12 Terres W, Hamm CW, Ruchelka A, Weilepp A, Kupper W. Residual platelet function under acetylsalicylic acid and the risk of restenosis after coronary angioplasty. J Cardiovasc Pharmacol 1992; 19: 190-3.
• 13 Hermans WR, Rensing BJ, Strauss BH, Serruys PW. Prevention of restenosis after percutaneous transluminal coronary angioplasty: the search for a “magic bullet”. Am Heart J 1991; 122: 171-87.
• 14 Isner JM, Rosenfiled K. Redifining the treatment of peripheral artery disease Role of percutaneous revascularisation. Circulation 1993; 88: 1534-1557.
• 15 Pollak JF. Peripheral arterial diseases. In: Peripheral vascular snography: a practical guide. Pollak JF. ed. Baltimore: Williams & Wilkins; 1992: 247-302.
• 16 Chamley JCampbell, Campbell GR, Ross R. The smooth muscle cell in culture. Physiol Rev 1979; 59: 1-61.
• 17 Johnston KW, Rae M, Hogg-Johnston SA, Colapinto RF, Walker PM, Baird RJ, Sniderman KW, Kalman P. 5-years results of a prospective study of percutaneous transluminal angioplasty. Ann Surg 1987; 206: 403-13.
• 18 Herrman JP, Hermans WR, Vos J, Serruys PW. Pharmacological approaches to the prevention of restenosis following angioplasty The search for the Holy Grail? (Part II). Drugs 1993; 46: 249-62.
• 19 Tschopl M, Tsakiris DA, Marbet GA, Labs KH, Jager K. Role of hemostatic risk factors for restenosis in peripheral arterial occlusive disease after transluminal angioplasty. Arterioscl Thromb Vasc Biol 1997; 17: 3208-14.
• 20 Yang Y, Guzman LA, Lincoff AM, Gottsauner-Wolf M, Forudi F, Hart CE, Courtman DW, Ezban M, Ellis SG, Topol EJ. Influence of blockade at specific levels of the coagulation cascade on restenosis in a rabbit atherosclerotic femoral artery injury model. Circulation 1995; 92: 3041-50.
• 21 Maca T, Ahmadi R, Derfler K, Horl WH, Koppensteiner R, Minar E, Schneider B, Stumpflen A, Ehringer H. Elevated lipoprotein(a) and increased incidence of restenosis after femoropopliteal PTA. Rationale for the higher risk of recurrence in females? Atheroclerosis 1996; 127: 27-34.
• 22 Elezi S, Kastrati A, Pache J, Wehinger A, Hadamitzky M, Dirschinger J, Neumann FJ, Schomig A. Diabetes mellitus and the clinical and angiographical outcome after coronary stent replacement. J Am Coll Cardiol 1998; 32: 1866-73.